Back

The effect of spironolactone versus eplerenone on blood pressure targets in resistant hypertension patients.

1 September 2024 (14:00 - 14:50)
Organised by: Logo
Congress Presentation Part of: Secondary and resistant hypertension Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Larysa Mishchenko

M.D. Strazhesko National Scientific Center, Kyiv (Ukraine)

8 More presentations in this session

Presentation thumbnail
Prediction of outcome in malignant hypertension patients using machine learning: a report from the West Birmingham malignant hypertension registry
Doctor A. Argyris (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Ten-year outcomes in patients with hypertension and primary hyperaldosteronism undergoing surgical adrenalectomy versus medical therapy: data from the multinational collaborative network TriNetX
Doctor R. Belo Nunes (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Cerebral damage after malignant hypertensive crisis: cerebral MRI follow-up data
Doctor J. Liegey (Bordeaux, FR)
Abstract Slides Video
Presentation thumbnail
Impaired systemic microvascular function in patients with resistant arterial hypertension and microalbuminuria: an observational study
Doctor E. Tibirica (Rio de Janeiro, BR)
Abstract Slides Video
Presentation thumbnail
Semaglutide for the treatment of resistant hypertension
Doctor C. Kennedy (Dublin, IE)
Abstract Slides Video

Access the full session

Session thumbnail
Secondary and resistant hypertension

The Event

Event poster

ESC Congress 2024

1 September 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
The comparative antihypertensive efficacy of torasemide and mineralocorticoid receptor antagonists in patients with resistant hypertension
thumbnail
Congress Presentation
Efficacy of spironolactone in reducing the risk of cardiovascular events and long-term mortality in those with resistant hypertension: findings from the Anglo-Scandinavian Cardiac Outcomes Trial.
thumbnail
Congress Session
Novel drug therapies in hypertension: new kids on the block

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources